Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 1
1(33.3%)
Phase 2
1(33.3%)
3Total
N/A(1)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02018653Not ApplicableTerminated

CASAD for Severe Diarrhea in the Emergency Department

Role: collaborator

NCT01570634Phase 2Terminated

Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection

Role: lead

NCT01739634Phase 1Unknown

The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

Role: lead

All 3 trials loaded